Lixte Biotech Hlds (LIXT)

$4.87 +0.90 (22.67%)
Market Cap 13.07M
Revenue (ttm) 0.00
Net Income (ttm) -3.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 294,200
Avg Vol 2,578,896
Day's Range N/A - N/A
Shares Out 2.68M
Stochastic %K 99%
Beta 0.41
Analysts Strong Buy
Price Target N/A

Company Profile

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab t...

Industry: Biotechnology
Sector: Healthcare
Phone: 631 830 7092
Fax: 631 982 5050
Website: lixte.com
Address:
680 East Colorado Boulevard, Suite 180, Pasadena, United States
StockScanners
StockScanners Aug. 2 at 9:21 PM
$LIXT keep watch if this holds above 3.80
0 · Reply
stockusfrance
stockusfrance Aug. 1 at 8:18 PM
$LIXT 0.80 to 4.80 Why ?
2 · Reply
Mitch___Picks
Mitch___Picks Aug. 1 at 7:26 PM
$LIXT new momentum swing idea. Been liking these type of swings more than my traditional swings lately. Starting to breakout today. Would like to hold this for a week or so.
0 · Reply
MythicalDragon
MythicalDragon Jul. 30 at 12:10 AM
$LIXT Looks good imo
0 · Reply
MarianChavis603
MarianChavis603 Jul. 28 at 3:09 PM
$LIXT targets cancer therapies, while AITX is healing inefficiencies in the $50B+ security industry—and the valuation gap says it’s underappreciated.
0 · Reply
Orlandotrader
Orlandotrader Jul. 25 at 6:45 PM
$LIXT Ascending Pennant!!! We go Higher.
0 · Reply
DavidScott
DavidScott Jul. 25 at 3:41 AM
On watch tomorrow (swing trading) // Part 2 🔥📈📚 $FFAI $FRSX $LIXT $SIDU $GME
0 · Reply
stockanalysis_
stockanalysis_ Jul. 24 at 12:54 AM
$ABVX $VOR $BMNR $TDTH $LIXT
0 · Reply
ElaineReyes472
ElaineReyes472 Jul. 23 at 5:03 PM
$LIXT is speculative biotech, but if you like real traction, RMTG is growing from Argentina to Puerto Rico—same model, fresh markets.
0 · Reply
stockanalysis_
stockanalysis_ Jul. 23 at 3:15 PM
Month Gainers: $ABVX $VOR $BMNR $TDTH $LIXT View the entire list here: https://stockanalysis.com/markets/gainers/month/?ref=saveontrading
0 · Reply
Latest News on LIXT
LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements

Jul 16, 2025, 8:05 AM EDT - 18 days ago

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq's Continued Listing Requirements

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering

Jul 9, 2025, 5:15 PM EDT - 25 days ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $1.5 Million Registered Direct Offering

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

Jul 9, 2025, 8:05 AM EDT - 25 days ago

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE's Ongoing Ovarian and Colorectal Cancer Trials

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement

Jul 8, 2025, 2:57 PM EDT - 26 days ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $5.0 Million Private Placement

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

Jul 2, 2025, 4:05 PM EDT - 4 weeks ago

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

Jul 1, 2025, 4:15 PM EDT - 4 weeks ago

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

Mar 31, 2025, 8:30 AM EDT - 4 months ago

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

Mar 27, 2025, 8:30 AM EDT - 4 months ago

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

Feb 25, 2025, 8:30 AM EST - 5 months ago

LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 13, 2025, 10:35 AM EST - 6 months ago

LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Feb 11, 2025, 8:42 AM EST - 6 months ago

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

Feb 10, 2025, 5:00 PM EST - 6 months ago

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

Sep 4, 2024, 8:30 AM EDT - 11 months ago

LIXTE Receives U.S. Patent Issue Notification for Immune Oncology

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

Aug 26, 2024, 8:30 AM EDT - 1 year ago

First Patient Dosed with LIXTE's LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborating with NKI, Supported by Major Pharma Company

LIXTE Biotechnology Provides Update On Recent Activities and Developments

Aug 19, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Provides Update On Recent Activities and Developments

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

Aug 15, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings to Present at Two Investor Conferences

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

Aug 14, 2024, 10:50 PM EDT - 1 year ago

Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

Jun 14, 2024, 11:00 AM EDT - 1 year ago

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

Jun 14, 2024, 9:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

Jun 6, 2024, 8:30 AM EDT - 1 year ago

Scientific Journal Reports Findings that Show LIXTE's Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

Jun 3, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

LIXTE Biotechnology Holdings Provides Update on Recent Activities

May 20, 2024, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings Provides Update on Recent Activities

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”

May 8, 2024, 9:25 AM EDT - 1 year ago

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Mar 21, 2024, 8:30 AM EDT - 1 year ago

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research

Feb 27, 2024, 8:30 AM EST - 1 year ago

Professor René Bernards to Present New Pre-Clinical Data on LIXTE's LB-100 at Joint Conference of European and American Associations for Cancer Research

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

Feb 26, 2024, 8:30 AM EST - 1 year ago

LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI

First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

Jan 29, 2024, 8:30 AM EST - 1 year ago

First Patient Dosed with LIXTE's LB-100 and GSK's Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

Nov 13, 2023, 8:30 AM EST - 1 year ago

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

Oct 9, 2023, 8:30 AM EDT - 1 year ago

LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

Sep 26, 2023, 8:30 AM EDT - 2 years ago

LIXTE Appoints Bas van der Baan as President and Chief Executive Officer

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE's First-in-Class PP2A Inhibitor, LB-100, Plus GSK's Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

Sep 20, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE's First-in-Class PP2A Inhibitor, LB-100, Plus GSK's Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

Jul 20, 2023, 4:05 PM EDT - 2 years ago

LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules

LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

Jun 23, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements

LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE's Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas

Jun 7, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE's Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas

LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023

Jun 2, 2023, 12:30 PM EDT - 2 years ago

LIXTE Biotechnology Holdings, Inc. Announces 1-for-10 Reverse Stock Split of its Common Stock Effective on Pre-Market Opening on June 5, 2023

Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology's Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy

May 30, 2023, 8:30 AM EDT - 2 years ago

Recently Published Independent Research Reveals New Mechanisms by Which LIXTE Biotechnology's Lead Clinical Compound, LB-100, Increases Effectiveness of Cancer Immunotherapy

LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma

Apr 24, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Reports First Spanish Site Activated to Begin Accrual of Patients for a Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, LB-100, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma

LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope's Ongoing Phase 1b Clinical Trial in Evaluating Lixte's Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer

Apr 4, 2023, 8:30 AM EDT - 2 years ago

LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope's Ongoing Phase 1b Clinical Trial in Evaluating Lixte's Lead Anti-Cancer Compound, LB-100, in Small Cell Lung Cancer

LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH

Feb 14, 2023, 1:50 PM EST - 2 years ago

LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH

LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS

Feb 7, 2023, 12:16 PM EST - 2 years ago

LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS

LIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor Conference

Nov 30, 2022, 8:05 AM EST - 2 years ago

LIXTE Biotechnology Holdings to Present at Planet MicroCap Showcase: VIRTUAL 2022 Investor Conference

LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP

Oct 13, 2022, 8:30 AM EDT - 3 years ago

LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS

Jun 21, 2022, 8:30 AM EDT - 3 years ago

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS

Jun 15, 2022, 8:30 AM EDT - 3 years ago

LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS

5 Short Squeeze Candidates To Watch This Week: Aterian, Harbor Custom Development Remain At The Top, Veru Joins

May 2, 2022, 10:45 AM EDT - 3 years ago

5 Short Squeeze Candidates To Watch This Week: Aterian, Harbor Custom Development Remain At The Top, Veru Joins

ATER VERU ZYME

LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market

Apr 14, 2022, 6:45 PM EDT - 3 years ago

LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market

WallachBeth Capital Announces Completion of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) $5.8 Million Registered Direct Offering

Apr 14, 2022, 2:54 PM EDT - 3 years ago

WallachBeth Capital Announces Completion of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) $5.8 Million Registered Direct Offering

WestPark Capital Announces Completion of $5.8 Million Registered Direct Offering Priced At-The-Market for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)

Apr 13, 2022, 9:00 AM EDT - 3 years ago

WestPark Capital Announces Completion of $5.8 Million Registered Direct Offering Priced At-The-Market for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)

WallachBeth Capital Announces Purchase and Sale of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT)

Apr 13, 2022, 8:30 AM EDT - 3 years ago

WallachBeth Capital Announces Purchase and Sale of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT)

LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market

Apr 12, 2022, 1:53 PM EDT - 3 years ago

LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market

StockScanners
StockScanners Aug. 2 at 9:21 PM
$LIXT keep watch if this holds above 3.80
0 · Reply
stockusfrance
stockusfrance Aug. 1 at 8:18 PM
$LIXT 0.80 to 4.80 Why ?
2 · Reply
Mitch___Picks
Mitch___Picks Aug. 1 at 7:26 PM
$LIXT new momentum swing idea. Been liking these type of swings more than my traditional swings lately. Starting to breakout today. Would like to hold this for a week or so.
0 · Reply
MythicalDragon
MythicalDragon Jul. 30 at 12:10 AM
$LIXT Looks good imo
0 · Reply
MarianChavis603
MarianChavis603 Jul. 28 at 3:09 PM
$LIXT targets cancer therapies, while AITX is healing inefficiencies in the $50B+ security industry—and the valuation gap says it’s underappreciated.
0 · Reply
Orlandotrader
Orlandotrader Jul. 25 at 6:45 PM
$LIXT Ascending Pennant!!! We go Higher.
0 · Reply
DavidScott
DavidScott Jul. 25 at 3:41 AM
On watch tomorrow (swing trading) // Part 2 🔥📈📚 $FFAI $FRSX $LIXT $SIDU $GME
0 · Reply
stockanalysis_
stockanalysis_ Jul. 24 at 12:54 AM
$ABVX $VOR $BMNR $TDTH $LIXT
0 · Reply
ElaineReyes472
ElaineReyes472 Jul. 23 at 5:03 PM
$LIXT is speculative biotech, but if you like real traction, RMTG is growing from Argentina to Puerto Rico—same model, fresh markets.
0 · Reply
stockanalysis_
stockanalysis_ Jul. 23 at 3:15 PM
Month Gainers: $ABVX $VOR $BMNR $TDTH $LIXT View the entire list here: https://stockanalysis.com/markets/gainers/month/?ref=saveontrading
0 · Reply
Trajdiiiiiiiie
Trajdiiiiiiiie Jul. 23 at 2:12 PM
$LIMN $SBET $BMNR $LIXT $IXHL flippers and paperhands out … we Know real run start always and of day!!!
0 · Reply
Aras198
Aras198 Jul. 23 at 11:59 AM
$FFAI $BULL $LIXT $MLGO $HOLO
0 · Reply
Orlandotrader
Orlandotrader Jul. 23 at 11:18 AM
$LIXT New Highs inbound.
0 · Reply
DavidScott
DavidScott Jul. 23 at 3:15 AM
On watch tomorrow (swing trading) // Part 2 🔥📈📚 $FFAI $BULL $LIXT $MLGO $HOLO
1 · Reply
Garymoved
Garymoved Jul. 22 at 8:03 PM
$BULL $FFAI $KSS $LIXT $OPEN Oh God this guy comes along when it’s all over! Ugh tell us before you go in! Or did I miss your post?
0 · Reply
DavidScott
DavidScott Jul. 22 at 8:02 PM
$OPEN $KSS $FFAI $BULL $LIXT = Nice job everyone! The bulls had some fantastic movers today, and were quite in control this session. These were our best trades, and we are bullish and expecting even more momentum on these names again going into Wednesday! If you need any guidance or a mentor, then feel free to join our team anytime ✅🙌 Have a great rest of the day everybody! 🎉
1 · Reply
tshark2107
tshark2107 Jul. 22 at 7:40 PM
$LIXT Why does FinViz say the float size is only 2.5 Million Shares when $LIXT just had a public offering on July 10th of 12.5 Million more shares? What am I missing? Love this stock, just don't want to get caught in a dilution.
1 · Reply
DavidScott
DavidScott Jul. 21 at 3:22 AM
On watch tomorrow (swing trading) // Part 2 🔥📈📚 $BULL $WWR $LIXT $GOVX $INO
0 · Reply
NextRunnerTV
NextRunnerTV Jul. 21 at 2:21 AM
$RSLS 🚨NEW VIDEO🚨 Follow like and subsrcibe. Merger Vote Thursday $120M Valuation on Deck? This Was $60 Not Long Ago! https://www.tiktok.com/@nextrunnertv/video/7529353044232883511?is_from_webapp=1&sender_device=pc&web_id=7508604446427924010 $KZIA $LGVN $LIXT $NVTS
0 · Reply
DavidScott
DavidScott Jul. 18 at 8:06 PM
$UAVS $BULL $WWR $LIXT $AMC = Awesome work bulls! It was another good round today. Great job everybody! These were our team's main trades this session. We are bullish and expecting even more action on these names again going into Monday. If you need any guidance or a mentor, then feel free to join our team anytime! ✅🤝 Have a great weekend everyone! 🎉
1 · Reply
Orlandotrader
Orlandotrader Jul. 18 at 8:02 PM
$LIXT Nice
0 · Reply
Discourse
Discourse Jul. 18 at 6:44 PM
$LIXT @diagio @ricky_lafleur this one quietly crawled back up to 4.20 as well. might be something cooking in the background here for some later day
1 · Reply